Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis

Bernard Charbonnel (), Dominique Simon (), Jean Dallongeville (), Isabelle Bureau (), Sylvie Dejager (), Laurie Levy-Bachelot (), Julie Gourmelen () and Bruno Detournay ()
Additional contact information
Bernard Charbonnel: Hôtel Dieu Hospital
Dominique Simon: Pitié Hospital
Jean Dallongeville: INSERM-U1167
Isabelle Bureau: Cemka-Eval
Sylvie Dejager: Merck Sharpe & Dohme
Laurie Levy-Bachelot: Merck Sharpe & Dohme
Julie Gourmelen: INSERM UMS 011
Bruno Detournay: Cemka-Eval

PharmacoEconomics - Open, 2018, vol. 2, issue 2, No 12, 209-219

Abstract: Abstract Objectives Our objects was to estimate the direct healthcare costs of type 2 diabetes mellitus (T2DM) in France in 2013. Methods Data were drawn from a random sample of ≈600,000 patients registered in the French national health insurances database, which covers 90% of the French population. An algorithm was used to select patients with T2DM. Direct healthcare costs from a collective perspective were derived from the database and compared with those from a control group to estimate the cost of diabetes and related comorbidities. Overall direct costs were also compared according to the diabetes therapies used throughout the year 2013. Results Cost analysis was available for a sample of 25,987 patients with T2DM (mean age 67.5 ± standard deviation 12.5; 53.9% male) matched with a control group of 76,406 individuals without diabetes. Overall per patient per year medical expenditures were €6506 ± 10,106 in the T2DM group as compared with €3668 ± 6954 in the control group. The cost difference between the two groups was €2838 per patient per year, mainly due to hospitalizations, medication and nursing care costs. Total per capita annual costs were lowest for patients receiving metformin monotherapy (€4153 ± 6170) and highest for those receiving insulin (€12,890). However, apart from patients receiving insulin, costs did not differ markedly across the different oral treatment patterns. Conclusion Extrapolating these results to the whole T2DM population in France, total direct costs of diagnosed T2DM in 2013 was estimated at over €8.5 billion. This estimate highlights the substantial economic burden of this condition on society.

Date: 2018
References: View complete reference list from CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
http://link.springer.com/10.1007/s41669-017-0050-3 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:2:y:2018:i:2:d:10.1007_s41669-017-0050-3

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-017-0050-3

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().